細(xì)胞程序性死亡蛋白1(PD1)重組蛋白
Recombinant Programmed Cell Death Protein 1 (PD1)
CD279; PDCD1; SLEB2; HPD1P
- 編號(hào)RPA751Ca01
- 物種Canis familiaris; Canine (Dog,犬)相同的名稱,不同的物種。
- 來(lái)源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位細(xì)胞膜
- 預(yù)測(cè)分子量35.3kDa
- 實(shí)際分子量38&36kDa(差異分析請(qǐng)參閱說(shuō)明書(shū))
- 片段與標(biāo)簽Met1~Pro288 with N-terminal His Tag
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 95%
- 等電點(diǎn)4.7
- 應(yīng)用Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,請(qǐng)參見(jiàn)活性蛋白。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格10μg50μg200μg1mg5mg
- 價(jià)格¥ 1195 ¥ 2988¥ 5976¥ 17928¥ 44820
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
序列

用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月,-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定,具體方法如下:在37°C孵育48小時(shí),沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi),在適當(dāng)?shù)臈l件下存儲(chǔ),損失率低于5%。
增值服務(wù)
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Canis familiaris; Canine (Dog,犬) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
EPA751Ca62 | 細(xì)胞程序性死亡蛋白1(PD1)真核蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPA751Ca01 | 細(xì)胞程序性死亡蛋白1(PD1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RAA751Ca81 | 細(xì)胞程序性死亡蛋白1(PD1)重組抗體 | WB; IF; ICC; IHC; IP; FCM. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Oncotarget | Circulating soluble programmed death-1 levels may differentiate immune-tolerant phase from other phases and hepatocellular carcinoma from other clinical diseases in chronic hepatitis B virus infection.[pubmed:28545019] |
CyberLeninka | Потенциальные биомаркеры эффективности терапии ниволумабом при метастатическом почечно-клеточном раке[:] |
АНАЛИЗ РЕЗУЛЬТАТОВ ЛЕЧЕНИЯ БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ ПОЧКИ, ПОЛУЧАВШИХ АНТИ-PD-1?ТЕРАПИЮ В РАМКАХ ПРОГРАММЫ?…[] | |
International Journal of Molecular?Sciences | Design and Synthesis of A PD-1 Binding Peptide and Evaluation of Its Anti-Tumor Activity[Pubmed: 30699956] |
PLoS?One | Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated?…[Pubmed: 30807610] |
Cancers | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study[Pubmed: 32085544] |